Angela Wolford
Pfizer (United States)(US)
Publications by Year
Research Areas
Drug Transport and Resistance Mechanisms, Pharmacogenetics and Drug Metabolism, Metabolism, Diabetes, and Cancer, Neutrophil, Myeloperoxidase and Oxidative Mechanisms, Synthesis and Biological Evaluation
Most-Cited Works
- → Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy(2016)115 cited
- → A Novel Relay Method for Determining Low-Clearance Values(2012)109 cited
- → A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling(2014)77 cited
- → Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)(2015)68 cited
- → Immune-Mediated Agranulocytosis Caused by the Cocaine Adulterant Levamisole: A Case for Reactive Metabolite(s) Involvement(2012)66 cited
- → Utility of the carboxylesterase inhibitorbis-para-nitrophenylphosphate (BNPP) in the plasma unbound fraction determination for a hydrolytically unstable amide derivative and agonist of the TGR5 receptor(2010)62 cited
- → Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases(2015)57 cited
- → Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists(2012)47 cited
- → Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans(2015)32 cited
- → Optimization of triazole-based TGR5 agonists towards orally available agents(2012)31 cited